IN-VITRO ANTI-HELICOBACTER PYLORI ACTIVITY OF EBROTIDINE

The in vitro anti-Helicobacter pylori (H. pylori) activity of ebrotidi ne ethyl]amino]methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) versus ranitidine, and their effect on the susceptibility to the antimicrobial agents used in H. pylori eradication were investiga ted. Assessment was performed by determining the minimum inhibitory co ncentrations (MIG) against 9 strains of H. pylori, 8 from clinical sou rce and 1 from the American Type Culture Collection (ATCC 43504), in M ueller-Hinton solid media plus 7 % blood. The concentration of inocula was 10(7) CFU/ml, incubation was performed at 37 degrees C in microae rophilic atmosphere, and results were read after 5 days of growth. Ebr otidine gave a mean MIC value of 75 mu g/ml, while that for ranitidine was > 1000 mu g/ml. Ebrotidine at 100 mu g/ml enhanced the activity o f the antimicrobials studied as follows: erythromycin 3 times, tetracy cline 1.1 times, amoxicillin 3 times, metronidazole-sensitive strains 9 times and clarithromycin 5 times. Ranitidine had no effect on the MI C of the antibiotics even al 500 mu g/ml.